We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
- Authors
Nauck, Michael A; Del Prato, Stefano; Meier, Juris J; Durán-García, Santiago; Rohwedder, Katja; Elze, Martina; Parikh, Shamik J
- Abstract
Although initially effective, sulfonylureas are associated with poor glycemic durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycemia by increasing urinary glucose excretion independent of insulin and may cause fewer of these adverse effects. We compared the efficacy, safety, and tolerability of dapagliflozin with the sulfonylurea glipizide in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
- Publication
Diabetes care, 2011, Vol 34, Issue 9, p2015
- ISSN
1935-5548
- Publication type
Journal Article
- DOI
10.2337/dc11-0606